Gailing Zhang

Statistics

Publications

Citations

303

H-Index

Active since

2019

Affiliations

Shijiazhuang Yiling Pharmaceutical (China)(Current)

Gailing Zhang is an author at Shijiazhuang Yiling Pharmaceutical (China) specializing in oncology, acute lymphoblastic leukemia therapy, and chimeric antigen receptor t-cell therapy.

Publications per year

2019–2022

Publications

Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features

Xian Zhang, Xin‐an Lu, Junfang Yang et al. · Blood Advances · 2020 · 215 citations · Full text

Medicine, Hematology, Oncology +14

Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation

Yu‐Hong Chen, Xian Zhang, Yifei Cheng et al. · Cytotherapy · 2020 · 42 citations

Medicine, Hematology, Oncology +16

Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma

Lefu Huang, Jingjing Li, Junfang Yang et al. · Cells · 2022 · 26 citations · Full text

Medicine, Immunology, Oncology +16

A Feasibility and Safety Study of a New CD19-Directed Fast CAR-T Therapy for Refractory and Relapsed B Cell Acute Lymphoblastic Leukemia

Junfang Yang, Jiaping He, Xian Zhang et al. · Blood · 2019 · 20 citations

Medicine, Hematology, Oncology +15

1–4 of 4